Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Total Liabilities: 2011-2025

Historic Total Liabilities for RedHill Biopharma (RDHL) over the last 10 years, with Jun 2025 value amounting to $22.8 million.

  • RedHill Biopharma's Total Liabilities rose 3.75% to $22.8 million in Q2 2025 from the same period last year, while for Jun 2025 it was $133.1 million, marking a year-over-year decrease of 57.54%. This contributed to the annual value of $22.7 million for FY2024, which is 8.33% up from last year.
  • Latest data reveals that RedHill Biopharma reported Total Liabilities of $22.8 million as of Q2 2025, which was up 0.27% from $22.7 million recorded in Q4 2024.
  • In the past 5 years, RedHill Biopharma's Total Liabilities registered a high of $203.2 million during Q3 2022, and its lowest value of $2.6 million during Q4 2022.
  • For the 3-year period, RedHill Biopharma's Total Liabilities averaged around $29.5 million, with its median value being $22.8 million (2024).
  • In the last 5 years, RedHill Biopharma's Total Liabilities crashed by 98.48% in 2022 and then soared by 699.77% in 2023.
  • Quarterly analysis of 5 years shows RedHill Biopharma's Total Liabilities stood at $172.3 million in 2021, then slumped by 98.48% to $2.6 million in 2022, then soared by 699.77% to $21.0 million in 2023, then rose by 8.33% to $22.7 million in 2024, then rose by 3.75% to $22.8 million in 2025.
  • Its Total Liabilities was $22.8 million in Q2 2025, compared to $22.7 million in Q4 2024 and $22.0 million in Q2 2024.